BioCentury
ARTICLE | Clinical News

Invega Sustenna: Phase III data

December 14, 2009 8:00 AM UTC

In a 13-week, double-blind, placebo-controlled Phase III trial in 1,220 patients, once-monthly Invega Sustenna met the primary endpoint of non-inferiority to biweekly Risperdal Consta risperidone in d...